Keywords: vaccine, cancer, immunotherapy, T-Cell Receptor, cancer testes antigen (CTA), placenta, NY-ESO-1
The Surgery Branch of the National Cancer Institute (NCI) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize vaccines for immunotherapy.
Scientists at the NCI developed a T cell receptor (TCR) derived from mouse T cells (i.e., murine TCR) that can be expressed in human T cells to recognize the cancer testis antigen (CTA), NY-ESO-1, with high specificity. This anti-NY-ESO-1 TCR has murine variable regions that recognize the NY-ESO-1 epitope and murine constant regions. The inventors performed in vitro studies comparing this murine NY-ESO-1 TCR with a previously developed human NY-ESO-1 TCR counterpart, which yielded promising clinical outcomes in patients with a variety of cancers. The murine TCR functioned similarly to the human counterpart in their ability to recognize and react to NY-ESO-1 tumor targets.
NY-ESO-1 is a CTA that is expressed only on tumor cells and germline cells of the testis and placenta. CTAs
are ideal targets for developing cancer immunotherapeutics, such as anti-CTA TCRs, since these TCRs are
expected to target cancer cells without harming normal tissues and thereby minimize the harsh side effects
associated with other types of cancer treatment. NY-ESO-1 is expressed on a wide variety of cancers, including
but not limited to breast, lung, prostate, thyroid, and ovarian cancers, melanoma, and synovial sarcomas, so
this technology should be applicable in adoptive cell transfer therapies for many types of cancer.
Potential Commercial Applications:
Development Stage: Discovery, in vitro data available.
Patent Status: U.S. Provisional Application No. 61/650,020 filed 22 May 2012.
Related Technologies: HHS Reference No. E-304-2006 and HHS Reference No. E-312-2007/1
Steven A. Rosenberg, M.D., Ph.D.
Last updated: 07/05/2012